A Randomized Clinical Trial of Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Kidney Transplant Rejection

In a small phase 2 trial, the anti-IL-6 antibody clazakizumab lowered donor-specific antibodies and slowed the decline in kidney function in transplant recipients with late antibody-mediated rejection, but serious infections signaled the need for caution.